An Orally Bioavailable Oxime Ether Capsid Binder with Potent Activity against Human Rhinovirus

Authors

K. G. Watson
R. N. Brown
R. Cameron
D. K. Chalmers
S. Hamilton
B. Jin
G. Y. Krippner
A. Luttick
D. B. McConnell
P. A. Reece
J. Ryan
P. C. Stanislawski
S. P. Tucker
W-Y Wu
Dale L. Barnard, Utah State UniversityFollow
R. W. Sidwell

Document Type

Article

Journal/Book Title/Conference

Journal of Medicinal Chemistry

Volume

46

Issue

15

Publisher

American Chemical Society

Publication Date

2003

First Page

3181

Last Page

3184

Abstract

A series of capsid-binding compounds was screened against human rhinovirus (HRV) using a CPE based assay. The ethyl oxime ether 14 was found to have outstanding anti-HRV activity (median IC50 4.75 ng/mL), and unlike the equivalent ethyl ester compound 3 (Pirodavir), it has good oral bioavailability, making it a promising development candidate. Compound 14 illustrates that an oxime ether group can act as a metabolically stable bioisostere for an ester functionality.

Comments

Originally published by the American Chemical Society. Publisher's PDF and HTML fulltext available through remote link.

Recommended Citation

Watson, K.G., Brown, R.N., Cameron, R., Chalmers, D.K., Hamilton, S., Jin, B., Krippner, G.Y., Luttick,....Barnard, D.L., Sidwell, R.W 2003. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. Journal of Medicinal Chemistry, 46(15): 3181-3184.